Document is current
Any future updates will be listed below
-
Authors
Louissaint, Jeremy https://orcid.org/0000-0003-1154-1825
Foster, Chelsey
Harding-Theobald, Emily
Lok, Anna S.
Tapper, Elliot B.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32DK062708)
National Institutes of Health (K23DK117055)
- License Information
-
More Information
Article History
Received: 1 March 2020
Accepted: 14 June 2020
First Online: 23 June 2020
Compliance with Ethical Standards
:
: Elliot Tapper has served as a consultant to Norvartis and Allergan, has served on advisory boards for Mallinckrodt and Bausch Health, and has received unrestricted research grants from Gilead and Valeant. Valeant is the maker of Rifaximin, a medication approved for treatment of hepatic encephalopathy. No other author has a conflict of interest.
